These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22681723)

  • 21. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease.
    Jia J; Wei C; Chen W; Jia L; Zhou A; Wang F; Tang Y; Xu L
    J Alzheimers Dis; 2020; 74(1):199-211. PubMed ID: 31985467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.
    Christensen DD
    Postgrad Med; 2012 Nov; 124(6):110-6. PubMed ID: 23322144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial.
    Hong YJ; Han HJ; Youn YC; Park KW; Yang DW; Kim S; Kim HJ; Kim JE; Lee JH;
    Alzheimers Res Ther; 2019 May; 11(1):37. PubMed ID: 31039806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
    Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
    Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
    Rogers SL; Friedhoff LT
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.
    Rogers SL; Doody RS; Pratt RD; Ieni JR
    Eur Neuropsychopharmacol; 2000 May; 10(3):195-203. PubMed ID: 10793322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia.
    Kwon JC; Kim EG; Kim JW; Kwon OD; Yoo BG; Yi HA; Choi NC; Ahn SY; Lee BH; Kang MJ; Choi DS;
    Am J Alzheimers Dis Other Demen; 2009; 24(4):293-301. PubMed ID: 19383979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
    Li DQ; Zhou YP; Yang H
    Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donepezil therapy in clinical practice: a randomized crossover study.
    Greenberg SM; Tennis MK; Brown LB; Gomez-Isla T; Hayden DL; Schoenfeld DA; Walsh KL; Corwin C; Daffner KR; Friedman P; Meadows ME; Sperling RA; Growdon JH
    Arch Neurol; 2000 Jan; 57(1):94-9. PubMed ID: 10634454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
    Relkin NR; Reichman WE; Orazem J; McRae T
    Dement Geriatr Cogn Disord; 2003; 16(1):15-24. PubMed ID: 12714795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
    Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
    Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
    Ikeda M; Mori E; Kosaka K; Iseki E; Hashimoto M; Matsukawa N; Matsuo K; Nakagawa M;
    Dement Geriatr Cogn Disord; 2013; 36(3-4):229-41. PubMed ID: 23949147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial.
    Hong YJ; Han HJ; Youn YC; Park KW; Yang DW; Kim S; Kim HJ; Kim HJ; Lee Y; Kwon M; Lee JH;
    Dement Geriatr Cogn Disord; 2021; 50(3):289-295. PubMed ID: 34518459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.